Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
2
PYXS Quote, Financials, Valuation and Earnings
Last price:
$1.11
Seasonality move
:
63.88%
Day range:
$1.08 - $1.16
52-week range:
$0.83 - $5.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
24.12x
P/B ratio:
1.00x
Volume:
1.4M
Avg. volume:
1.3M
1-year change:
-30.63%
Market cap:
$69.1M
Revenue:
$16.1M
EPS (TTM):
-$1.59
Analysts' Opinion
-
Consensus RatingPyxis Oncology, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.18, Pyxis Oncology, Inc. has an estimated upside of 546.4% from its current price of $1.11.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $1.11.
Fair Value
-
According to the consensus of 8 analysts, Pyxis Oncology, Inc. has 546.4% upside to fair value with a price target of $7.18 per share.
PYXS vs. S&P 500
-
Over the past 5 trading days, Pyxis Oncology, Inc. has underperformed the S&P 500 by -67.53% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Pyxis Oncology, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Pyxis Oncology, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Pyxis Oncology, Inc. reported revenues of --.
Earnings Growth
-
Pyxis Oncology, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Pyxis Oncology, Inc. reported earnings per share of -$0.35.
Enterprise value:
10.5M
EV / Invested capital:
0.12x
Price / LTM sales:
24.12x
EV / EBIT:
--
EV / Revenue:
3.71x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-0.14x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$656K
Return On Assets:
-67.69%
Net Income Margin (TTM):
-3442.77%
Return On Equity:
-90.91%
Return On Invested Capital:
-76.68%
Operating Margin:
-700.36%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $16.1M | $2.8M | -- | -- | |
| Gross Profit | -$2.2M | $12.5M | $656K | -$731K | -$527K | |
| Operating Income | -$102.4M | -$67.2M | -$85.2M | -$23.8M | -$23.5M | |
| EBITDA | -$100.2M | -$64M | -$83.1M | -$23M | -$22.9M | |
| Diluted EPS | -$2.55 | -$1.05 | -$1.59 | -$0.35 | -$0.35 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $134.3M | $202.8M | $139.1M | $148.9M | $83.1M | |
| Total Assets | $139.5M | $223.9M | $186.7M | $195.3M | $105.6M | |
| Current Liabilities | $16.8M | $19.1M | $28.3M | $20.3M | $19.4M | |
| Total Liabilities | $16.9M | $35.1M | $48.7M | $41.6M | $36.8M | |
| Total Equity | $122.6M | $188.7M | $137.9M | $153.7M | $68.8M | |
| Total Debt | $325K | $16.1M | $20.4M | $19.1M | $17.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$72.8M | -$53.6M | -$72.4M | -$14.6M | -$13.3M | |
| Cash From Investing | -$116.9M | -$8.3M | $69.3M | -$8K | $11.5M | |
| Cash From Financing | $6M | $59.2M | $54K | $1.6M | -$8K | |
| Free Cash Flow | -$81.4M | -$53.8M | -$72.5M | -$14.6M | -$13.3M | |
PYXS
Sector
Market Cap
$69.1M
$28M
Price % of 52-Week High
20%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
0.22%
-1.54%
1-Year Price Total Return
-30.63%
-17.48%
Beta (5-Year)
--
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.25
200-day SMA
Sell
Level
$1.99
Bollinger Bands (100)
Sell
Level
1.54 - 4.18
Chaikin Money Flow
Sell
Level
-7.8M
20-day SMA
Sell
Level
$3.57
Relative Strength Index (RSI14)
Sell
Level
20.22
ADX Line
Sell
Level
35.9
Williams %R
Buy
Level
-98.3003
50-day SMA
Sell
Level
$3.84
MACD (12, 26)
Buy
Level
0.35
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Sell
Level
-21.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.1566)
Sell
CA Score
(Annual)
Level (-1.1699)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (3.6917)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.
Stock Forecast FAQ
In the current month, PYXS has received 7 Buy ratings 1 Hold ratings, and 0 Sell ratings. The PYXS average analyst price target in the past 3 months is $7.18.
-
Where Will Pyxis Oncology, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Pyxis Oncology, Inc. share price will rise to $7.18 per share over the next 12 months.
-
What Do Analysts Say About Pyxis Oncology, Inc.?
Analysts are divided on their view about Pyxis Oncology, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Pyxis Oncology, Inc. is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Pyxis Oncology, Inc.'s Price Target?
The price target for Pyxis Oncology, Inc. over the next 1-year time period is forecast to be $7.18 according to 8 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is PYXS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Pyxis Oncology, Inc. is a Buy. 7 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PYXS?
You can purchase shares of Pyxis Oncology, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Pyxis Oncology, Inc. shares.
-
What Is The Pyxis Oncology, Inc. Share Price Today?
Pyxis Oncology, Inc. was last trading at $1.11 per share. This represents the most recent stock quote for Pyxis Oncology, Inc.. Yesterday, Pyxis Oncology, Inc. closed at $1.11 per share.
-
How To Buy Pyxis Oncology, Inc. Stock Online?
In order to purchase Pyxis Oncology, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PYXS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PYXS
Sector
P/E ratio
--
23.89x
PEG ratio
-0.01x
-0.01x
P/B ratio
1.00x
1.82x
Price / LTM sales
24.12x
1.60x
Growth Metrics
PYXS
Sector
Revenue growth
--
4.62%
Earnings growth
-0.72%
10.88%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.34
-$0.21
Profitability
PYXS
Sector
Profitability FY 2024
$12.7M
$3.5M
Return on invested capital
-76.68%
-31.77%
Return on assets
-67.69%
-27.96%
Return on equity
-90.91%
-37.63%
Earnings Date
Last Earnings Date
Nov
3
Next Earnings Date
Mar
18
Estimated Next Earnings Date
Feb
2
Balance Sheet
PYXS
Sector
Total cash
$77.7M
$26.3M
Short term investments
$107.5M
$25.7M
Total assets
$157.2M
$78M
Long term debt
$17.4M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
